Story perspectives

New Pancreatic Cancer Treatment Enters Phase 2 Trials

9/11/2025

50 6

Summary

Story summary

DZ-002 has begun Phase 2 clinical trials at HOAG Cancer Center for pancreatic cancer treatment.
The trials evaluate safety, dosage, and efficacy, essential for regulatory approval.
DZ-002 combines diagnostic imaging with targeted therapy to personalize treatment.
Developed by Georgia State University and Da Zen Theranostics, it uses a fluorescent dye-drug conjugate.
MHI-148 enhances tumor visualization and drug delivery, potentially improving treatment outcomes and patient quality of life.

1 of 1

Story summary

DZ-002 has begun Phase 2 clinical trials at HOAG Cancer Center for pancreatic cancer treatment.
The trials evaluate safety, dosage, and efficacy, essential for regulatory approval.
DZ-002 combines diagnostic imaging with targeted therapy to personalize treatment.
Developed by Georgia State University and Da Zen Theranostics, it uses a fluorescent dye-drug conjugate.
MHI-148 enhances tumor visualization and drug delivery, potentially improving treatment outcomes and patient quality of life.